

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab)
Recombinant Antibody
Catalog # APR10073**

Specification

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Product Information

Application	FC, E, FTA
Primary Accession	P32970
Reactivity	Cynomolgus, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.36 KDa

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Additional Information

Target/Specificity
TNFSF7 / CD27L / CD70

Endotoxin
< 0.001EU/ µg, determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Protein Information

Name CD70 ([HGNC:11937](#))

Function
Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed: [28011863](http://www.uniprot.org/citations/28011863), PubMed: [28011864](http://www.uniprot.org/citations/28011864), PubMed: [8387892](http://www.uniprot.org/citations/8387892)). The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed: [28011863](http://www.uniprot.org/citations/28011863), PubMed: [28011864](http://www.uniprot.org/citations/28011864)).


Cellular Location
Cell membrane; Single-pass type II membrane protein

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Images




Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) is more than 95%, determined by SEC-HPLC.



Immobilized human CD70 FC at 4 µg/mL can bind Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) EC₅₀=0.08279 µg/mL



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC₁₂₅=0.2727 µg/mL